BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27799309)

  • 1. Lung Cancer Subtypes Generate Unique Immune Responses.
    Busch SE; Hanke ML; Kargl J; Metz HE; MacPherson D; Houghton AM
    J Immunol; 2016 Dec; 197(11):4493-4503. PubMed ID: 27799309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.
    Shiao TH; Chang YL; Yu CJ; Chang YC; Hsu YC; Chang SH; Shih JY; Yang PC
    J Thorac Oncol; 2011 Jan; 6(1):195-8. PubMed ID: 21178714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.
    Koyama K; Kagamu H; Miura S; Hiura T; Miyabayashi T; Itoh R; Kuriyama H; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Gejyo F
    Clin Cancer Res; 2008 Nov; 14(21):6770-9. PubMed ID: 18980970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
    Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
    J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.
    Mansuet-Lupo A; Alifano M; Pécuchet N; Biton J; Becht E; Goc J; Germain C; Ouakrim H; Régnard JF; Cremer I; Laurent-Puig P; Dieu-Nosjean MC; Blons H; Damotte D
    Am J Respir Crit Care Med; 2016 Dec; 194(11):1403-1412. PubMed ID: 27299180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
    Kogan D; Grabner A; Yanucil C; Faul C; Ulaganathan VK
    J Clin Invest; 2018 May; 128(5):1867-1872. PubMed ID: 29438108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8(high)CD57(+) T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer.
    Dobrovolskienė NT; Cicėnas S; Kazlauskaitė N; Mišeikytė-Kaubrienė E; Krasko JA; Ostapenko V; Pašukonienė V; Strioga MM
    Lung Cancer; 2015 Nov; 90(2):326-33. PubMed ID: 26319316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
    J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of small cell lung cancer in a Japanese cohort.
    Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
    Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
    O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
    Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
    Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
    Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.
    Staaf J; Isaksson S; Karlsson A; Jönsson M; Johansson L; Jönsson P; Botling J; Micke P; Baldetorp B; Planck M
    Int J Cancer; 2013 May; 132(9):2020-31. PubMed ID: 23023297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma.
    Banat GA; Tretyn A; Pullamsetti SS; Wilhelm J; Weigert A; Olesch C; Ebel K; Stiewe T; Grimminger F; Seeger W; Fink L; Savai R
    PLoS One; 2015; 10(9):e0139073. PubMed ID: 26413839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
    Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
    Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung.
    Balabko L; Andreev K; Burmann N; Schubert M; Mathews M; Trufa DI; Reppert S; Rau T; Schicht M; Sirbu H; Hartmann A; Finotto S
    Sci Rep; 2014 Dec; 4():7396. PubMed ID: 25491772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
    Oser MG; Niederst MJ; Sequist LV; Engelman JA
    Lancet Oncol; 2015 Apr; 16(4):e165-72. PubMed ID: 25846096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.